Skip to main content

Day: March 13, 2025

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product

Written by Customer Service on . Posted in Public Companies.

No significant clinical adverse event observed in Phase 1clinical study Pharmacokinetic profile established and range of doses selected for Phase 2a Clinical Efficacy Study First patient expected to be treated in the Phase 2a Clinical Efficacy Study on March 14, 2025 at the Montreal Heart InstituteTORONTO, ONTARIO, March 13, 2025 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced Initiation of its Phase 2a clinical efficacy study of its flagship avenanthramides product being developed for potential applications in managing conditions related to inflammation. Avenanthramides are di-phenolic compounds found exclusively in...

Continue reading

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Written by Customer Service on . Posted in Public Companies.

Raanana, Israel, March 13, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, previously announced the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment. As previously announced, the study will be conducted in collaboration with Professor Fabio Sonvico, Associate Professor at the Department of Food and Drug of the University of Parma (Italy) a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company’s Scientific Advisory Board. These preclinical studies mark a step forward in evaluating Polyrizon’s Trap and Target™ (T&T) platform for the intranasal...

Continue reading

ZenaTech Expands ZenaDrone Team by 35 Engineers and Technicians to Meet Drone Production Manufacturing Capacity

Written by Customer Service on . Posted in Public Companies.

VANCOUVER, British Columbia, March 13, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions, announces today that its subsidiary ZenaDrone is expanding its team of drone engineers, technicians, and R&D engineers by adding 35 new hires to meet production line and capability requirements for the manufacturing of its drone products. “As we transition from the prototype stages to full-scale production of our drones, we are adding qualified engineering, manufacturing and technical talent to commence and accelerate full-scale manufacturing and assembly. Expanding our production line capacity by adding these resources is a critical step...

Continue reading

Advanced Flower Capital Inc. Announces Financial Results for Fourth Quarter and Full Year 2024

Written by Customer Service on . Posted in Dividend Reports And Estimates.

Fourth quarter 2024 GAAP net loss of $(1.0) million or $(0.05) per basic weighted average common share and Distributable Earnings¹ of $6.3 million or $0.29 per basic weighted average common share Full year 2024 GAAP net income of $16.8 million or $0.78 per basic weighted average common share and Distributable Earnings of $34.9 million or $1.68 per basic weighted average common share Dividend declared of $0.23 per common share for the first quarter 2025 WEST PALM BEACH, Fla., March 13, 2025 (GLOBE NEWSWIRE) — Advanced Flower Capital Inc. (f/k/a AFC Gamma, Inc.) (NASDAQ:AFCG) (“Advanced Flower Capital”, “AFC” or the “Company”) today announced its results for the fourth quarter and year ended December 31, 2024. AFC reported generally accepted accounting principles (“GAAP”) net loss of $(1.0) million or $(0.05) per basic weighted average...

Continue reading

Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

– Announced positive data from Phase 1 clinical trial evaluating VG-3927 for potential treatment of Alzheimer’s Disease (AD); plans to initiate Phase 2 clinical trial in Q3 2025 – – On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – WATERTOWN, Mass., March 13, 2025 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided updates on recent progress. “We are entering 2025 with strong momentum, driven by significant progress in the development of our TREM2 programs, VG-3927 and iluzanebart,” said Ivana Magovčević-Liebisch, Ph.D.,...

Continue reading

Form 8.3 – Primary Health Properties

Written by Customer Service on . Posted in Mergers And Acquisitions.

FORM 8.3 Amendment – this Rule 8.3 Disclosure replaces the Rule 8.3 Disclosure published at 14:52 on 21/02/25. Changes have been made to Section 2(a). PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.         KEY INFORMATION(a) Full name of discloser: Foresight Group LLP(b) Owner or controller of interests and short positions disclosed, if different from 1(a):     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates:     Use a separate form for each offeror/offeree Primary Health Properties(d) If an exempt fund manager connected...

Continue reading

Form 8.3 – Primary Health Properties

Written by Customer Service on . Posted in Mergers And Acquisitions.

FORM 8.3 Amendment – this Rule 8.3 Disclosure replaces the Rule 8.3 Disclosure published at 14:52 on 21/02/25. Changes have been made to Section 2(a). PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.         KEY INFORMATION(a) Full name of discloser: Foresight Group LLP(b) Owner or controller of interests and short positions disclosed, if different from 1(a):     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates:     Use a separate form for each offeror/offeree Primary Health Properties(d) If an exempt fund manager connected...

Continue reading

Form 8.3 – Primary Health Properties

Written by Customer Service on . Posted in Mergers And Acquisitions.

FORM 8.3 Amendment – this Rule 8.3 Disclosure replaces the Rule 8.3 Disclosure published at 14:52 on 21/02/25. Changes have been made to Section 2(a). PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.         KEY INFORMATION(a) Full name of discloser: Foresight Group LLP(b) Owner or controller of interests and short positions disclosed, if different from 1(a):     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates:     Use a separate form for each offeror/offeree Primary Health Properties(d) If an exempt fund manager connected...

Continue reading

Jeffs’ Brands Achieves an Important Milestone Towards Completion of Fort’s Proposed Merger with a Publicly Traded Company – Receives Valuation Report of Fort for Approximately US$11.6 – US$14.2 Million

Written by Customer Service on . Posted in Mergers And Acquisitions.

Tel Aviv, Israel, March 13, 2025 (GLOBE NEWSWIRE) — Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, today announced that further to its press release dated February 6, 2025, regarding the definitive agreement to complete the contemplated merger of Fort Products Limited, a U.K.-based private company and a wholly owned subsidiary of the Company (“Fort Products”), with Impact Acquisitions Corp. (“Impact”), a capital pool company listed on the TSX Venture Exchange (the “Proposed Merger”), Impact has obtained a valuation report from Evans & Evans, Inc. (“Evans & Evans”), which indicates that in the opinion of Evans & Evans, the fair market value of the equity interests of Fort Products as of January 31, 2025, is between...

Continue reading

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) Assuming FDA approval, proposed launch in PSVT targeted for mid-2025 Milestone well-capitalized to commercialize upon approval with royalty financing MONTREAL and CHARLOTTE, N.C., March 13, 2025 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided a regulatory and corporate update. “We are focused on the potential FDA approval for CARDAMYST and the opportunity to help the millions of patients suffering from PSVT,” said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. “Our launch preparations are well underway. We have resources secured...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.